Human Vaccines & Immunotherapeutics (Jan 2022)

Immunogenicity and safety of human diploid cell vaccine (HDCV) vs. purified Vero cell vaccine (PVRV) vs. purified chick embryo cell vaccine (PCECV) used in post-exposure prophylaxis: a systematic review and meta-analysis

  • Shi-Yuan Wang,
  • Jin-Fang Sun,
  • Pei Liu,
  • Li Luo,
  • Jing-Xin Li,
  • Feng-Cai Zhu,
  • Xu-Xiang Shen,
  • Fan-Yue Meng

DOI
https://doi.org/10.1080/21645515.2022.2027714
Journal volume & issue
Vol. 18, no. 1

Abstract

Read online

This study comprehensively evaluated and compared three human rabies vaccines. Seven electronic databases were systematically searched. The Cochrane Handbook v5.1.0 was used to assess the risk of bias. A random-effects model was used to combine individual rates, and network meta-analysis was used for pairwise comparisons. Twenty-seven articles were included, with a total of 18,630 participants. The pooled incidence of the total adverse reaction to HDCV was significantly lower than that of PCECV. HDCV administration resulted in a lower incidence of local pain, fever, and weakness than purified Vero cell vaccine. HDCV caused a lower incidence of local pain and fever than PCECV. No significant difference was observed in terms of the seroconversion rate on day 7 or the rabies virus-neutralizing antibody titer on day 14. HDCV demonstrated superiority in terms of safety compared with the other two rabies vaccines, while the same was not observed in terms of immunogenicity.

Keywords